AG
ATRA icon

Artal Group’s Atara Biotherapeutics ATRA Stock Holding History

Artal Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,000
Closed -$7.79M – 139
2022
Q2 		$7.79M Hold
40,000
– – 0.42% 44
2022
Q1 		$9.29M Sell
40,000
-20,000
-33% -$6.37M 0.39% 51
2021
Q4 		$23.6M Hold
60,000
– – 0.64% 40
2021
Q3 		$26.9M Hold
60,000
– – 0.6% 38
2021
Q2 		$23.3M Sell
60,000
-20,000
-25% -$7.13M 0.47% 46
2021
Q1 		$28.7M Sell
80,000
-32,000
-29% -$14.1M 0.51% 46
2020
Q4 		$55M Buy
112,000
+22,000
+24% +$10.2M 1.18% 24
2020
Q3 		$29.2M Sell
90,000
-10,000
-10% -$3.41M 0.71% 32
2020
Q2 		$36.4M Hold
100,000
– – 1.02% 24
2020
Q1 		$21.3M Buy
100,000
+30,000
+43% +$9.52M 0.9% 29
2019
Q4 		$28.8M Buy
70,000
+10,000
+17% +$3.45M 1.11% 19
2019
Q3 		$21.2M Buy
60,000
+14,000
+30% +$5.22M 0.85% 20
2019
Q2 		$23.1M Hold
46,000
– – 0.94% 26
2019
Q1 		$45.7M Buy
46,000
+6,000
+15% +$5.57M 1.87% 14
2018
Q4 		$34.7M Hold
40,000
– – 1.29% 18
2018
Q3 		$41.4M Hold
40,000
– – 1.08% 17
2018
Q2 		$36.8M Sell
40,000
-10,000
-20% -$10.7M 0.78% 18
2018
Q1 		$48.8M Buy
50,000
+10,000
+25% +$9.11M 0.61% 17
2017
Q4 		$18.1M Buy
40,000
+16,000
+67% +$5.91M 0.27% 32
2017
Q3 		$9.93M Buy
24,000
+4,000
+20% +$1.51M 0.17% 41
2017
Q2 		$7M Hold
20,000
– – 0.12% 44
2017
Q1 		$10.3M Hold
20,000
– – 0.23% 39
2016
Q4 		$7.1M Buy
20,000
+11,000
+122% +$4.66M 0.16% 46
2016
Q3 		$4.81M Buy
+9,000
New +$4.89M 0.1% 59

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Artal Group's ATRA Position: Q3 2022 in Review

Artal Group sold out of Atara Biotherapeutics (ATRA) in Q3 2022, closing a stake of 40,000 shares — an estimated $7.79M sold.

Artal Group first reported a position in ATRA in Q3 2016 and held it in 24 quarters. The position peaked at $55M in Q4 2020. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

  • Artal Group reported no remaining Atara Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Artal Group sold 40,000 Atara Biotherapeutics shares in Q3 2022, an estimated $7.79M.
  • Artal Group first reported a position in Atara Biotherapeutics in Q3 2016 and held it in 24 quarters.
  • Artal Group's Atara Biotherapeutics position peaked at $55M in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.